

Docket No. PRD2051USNP

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Bharat Lagu

Serial No.: 10/815,048

Art Unit:

Filed

: March 31, 2004

Examiner:

For

: PHOSPHOLIPASE C INHIBITORS FOR USE IN TREATING

INFLAMMATORY DISORDERS

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

August 15 2005

Thomas J. Dodd
(Name of applicant, assignes or Registered Representative)

(Signature)

August 15 2005
(Date of Signature)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §\$1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this

information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

In accordance with §1.97(b), since this Information \boxtimes Disclosure Statement is being filed either within three months of the filing date of the above-identified national application (other than a continued prosecution application under §1.53(d)), within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of a request for continued examination under §1.114, no additional fee is required. In accordance with \$1.129(a), this Information Disclosure Statement is being filed in connection with [] the first or ☐second After Final Submission, therefore: Statement in Accordance with §1.97(e) (attached); or П Please charge Deposit Account No. 10the fee of \$180.00 as set forth in \$1.17(p). In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in \$1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, or an action that otherwise closes prosecution and that it is accompanied by one of:

Statement in Accordance with \$1.97(e)
(attached); or
Please charge Deposit Account No. 10-
0750/ / the fee of $$180.00$ as set forth
in §1.17(p).
☐ In accordance with §1.97(d), this Information
Disclosure Statement is being filed after the mailing date of
either a Final Action under \$1.113 or a Notice of Allowance
under \$1.311 but before the payment of the Issue Fee.
Applicant(s) hereby petition(s) for consideration of this
Information Disclosure Statement. Included are: Statement in
Accordance with \$1.97(e) as set forth below and the fee of
\$180.00 as set forth in \$1.17(p).
<u> </u>
Copies of each of the references listed on the
attached Form PTO-1449 are enclosed herewith.
Copies of references listed on the attached Form PTO
1449 are enclosed herewith EXCEPT THAT:
In view of the voluminous nature of references
[list as appropriate], and the likelihood that
these references are available to the Examiner,
copies are not enclosed herewith.
If any of the foregoing publications are not
available to the Examiner, Applicant will
endeavor to supply copies at the Examiner's
request.
∇7
Copies of only foreign patent documents and non-
patent literature are enclosed in accordance with 37 CFR 1.98
(a) (2).

$oxed{\boxtimes}$ There are no listed references which are not in the
English language.
The relevance of those listed references which are
not in the English language is as follows:
Attached are copies of search report(s) from
corresponding patent application(s), which are listed on the
attached Submission Under MPEP 609 D.
Attached are the following non-published pending
patent applications which may be deemed relevant, which are
listed on the attached Submission Under MPEP 609 D.

Please charge any deficiency or credit any overpayment to Deposit Account No. 10-0750/PRD2051USNP/TD. This form is submitted in triplicate.

Respectfully submitted,

Reg. No. 31,010

Attorney for Applicants

Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933-7003
(732) 524-2782
DATED: August 15 2005

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 1 of 1

a collection of information timess it displays a valid of the control number.				
Application Number	10/815,048			
Filing Date	March 31, 2004			
First Named Inventor	Bharat Lagu			
Group Art Unit				
Examiner Name				
Attorney Docket Number	PRD-2051			

FOREIGN PATENT DOCUMENTS Foreign Patent Document Date of Publication Pages, Columns, Lines, of Cited Document where relevant Name of Patentee or Examiner Cite passages or relevant mm-dd-yyyy Applicant of Cited Document Initials figures appear Number⁴ KindCode⁵ Office³ No.1 WO 96/10568 Merck & Co., Inc. et al. 04-11-1996 WO 02/32867 Glaxo Group Ltd. 04-25-2002

Examiner's		Include name of the author (in CARITAL LETTERS) title of the article (when appropriate) title of the item	
Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the catalog, etc.), date, page(s), volume-issue number nitials* No.1 Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the article (when appropriate), title of the article (when appropriate) title of the article (whe		T²	
		Chemical Abstract, Database - Chemcats, Catalog Name, Otava Stock Chemicals, Chemical Abstract Service, Columbus, Ohio, Order Nos. 7114960248, 7114960239, 7114960244 and 7114960243, September 24, 2003	

Examiner	Date	
Signature	Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA

22313-1450.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.